Diana A Koch

Suggest Changes
Learn More
OBJECTIVE Mitogen-activated protein kinase (MAPK) p38 inhibitors have entered the clinical phase, although many of them have failed due to high toxicity and lack of efficacy. In the present study we(More)
  • 1